Magnevist

(Gadopentetate dimeglumine)

PreclinicalSmall molecule

Bayer

Magnevist is one of 39 small molecule programs targeting Renal insufficiency. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Renal InsufficiencyActive, not recruiting

Meniere DiseaseActive, not recruiting

Renal InsufficiencyPreclinical

Active, not recruiting

Meniere DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

38 competitors in Renal Insufficiency

#DrugCompanyPhaseTrials

Victoza

Novo Nordisk

Approved

1 2

Jaypirca

Aliqopa

Gilenya

Retevmo

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

1 7

Genotropin

EMD Serono

Approved

1 8

Zocor

OOrganon and Co

Approved

1 9

Cubicin

BBaxter Healthcare Corporation

Approved

1 10

Imcivree

Rhythm Pharmaceuticals

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

ART4 trials

Magnevist® Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral Arteries

Completed· Bayer logo

Bayer·Phase 3·NCT00185276·365 enrolled

Magnevist® Injection-enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis of the Renal Arteries

Completed· Bayer logo

Bayer·Phase 3·NCT00310557·116 enrolled

A Comparison of Indirect and Direct MR Arthrography of the Shoulder Using Arthroscopic Correlation

Withdrawn·MMilton S. Hershey Medical Center·N/A·NCT01416740

Show 1 more trial

Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis in the Calf and/or Pedal Arteries

Completed· Bayer logo

Bayer·Phase 3·NCT00309075·126 enrolled

MPA2 trials

Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Aortic Arch and Cerebral Branches

Completed· Bayer logo

Bayer·Phase 3·NCT00310609·123 enrolled

Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance Angiography

Completed· Bayer logo

Bayer·Phase 2·NCT00652418·12 enrolled

Contrast Agent1 trial

Crossover Comparison of Two Gadolinium Contrast Agents for Use With MRA of Carotid, Renal and Peripheral Arteries

Completed·BBracco Diagnostics, Inc·Phase 3·NCT01260636·120 enrolled

Metastases1 trial

Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

Completed·SStanford University·Phase 2·NCT00375830·114 enrolled

Cardiovascular1 trial

Cardiovascular Safety Study of Magnevist® Injection at Two Dose Levels and Two Injection Rates in Normal Subjects

Completed· Bayer logo

Bayer·Phase 1·NCT00310596·71 enrolled

4 more indications

Renal insufficiency1 trial

Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist

Completed· Bayer logo

Bayer··NCT00744939·168 enrolled

Children1 trial

Contrast-enhanced MRI in Children 2 Months to <2 Years

Completed· Bayer logo

Bayer·Phase 3·NCT00937391·54 enrolled

Meniere disease1 trial

Unilateral Meniere Disease: Can Double Dose Gadolinium and Delayed Imaging Make the Diagnosis?

Withdrawn·EEmory University·N/A·NCT02371798

Unspecified2 trials

Gadobutrol Magnevist-controlled Body Study

Completed· Bayer logo

Bayer·Phase 3·NCT01050829·370 enrolled

Magnevist Post-marketing Surveillance in Japan

Completed· Bayer logo

Bayer··NCT01376739·2,051 enrolled

Regulatory

FDA Approval Timeline[4]

Jun 2, 1988

MAGNEVIST

NDA NDA019596

Mar 10, 2000

MAGNEVIST

NDA NDA021037

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for Gadopentetate dimeglumine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gadopentetate dimeglumine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gadopentetate dimeglumine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA021037). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Bayer

Magnevist

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

ART4 trials

MPA2 trials

Contrast Agent1 trial

Metastases1 trial

Cardiovascular1 trial

Renal insufficiency1 trial

Children1 trial

Meniere disease1 trial

Unspecified2 trials

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News